Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc ADR (GSK)

Glaxosmithkline Plc ADR (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,468,944
  • Shares Outstanding, K 2,692,595
  • Annual Sales, $ 43,783 M
  • Annual Income, $ 7,382 M
  • 60-Month Beta 0.71
  • Price/Sales 2.38
  • Price/Cash Flow 9.98
  • Price/Book 3.45
Trade GSK with:

Options Overview Details

View History
  • Implied Volatility 21.63%
  • Historical Volatility 14.82%
  • IV Percentile 49%
  • IV Rank 18.06%
  • IV High 47.71% on 01/27/21
  • IV Low 15.88% on 08/27/21
  • Put/Call Vol Ratio 2.23
  • Today's Volume 5,786
  • Volume Avg (30-Day) 4,092
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 93,763
  • Open Int (30-Day) 108,654

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.80
  • Number of Estimates 4
  • High Estimate 0.84
  • Low Estimate 0.75
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.80 +4.39%
on 10/06/21
39.65 -0.48%
on 09/22/21
+0.61 (+1.57%)
since 09/20/21
3-Month
37.80 +4.39%
on 10/06/21
42.68 -7.54%
on 08/18/21
+0.37 (+0.95%)
since 07/20/21
52-Week
33.26 +18.64%
on 10/30/20
42.68 -7.54%
on 08/18/21
+3.42 (+9.49%)
since 10/20/20

Most Recent Stories

More News
These 5 Biotech Stocks are Getting Closer to Releasing NEW Covid-19 Vaccine Candidates

As the FDA moves to approve multiple booster shots for all of the available Covid-19 vaccines available ...

NVAX : 136.86 (-14.76%)
GSK : 39.46 (+0.74%)
SNY : 49.05 (+2.06%)
DVAX : 18.23 (+3.87%)
CVAC : 39.66 (-4.16%)
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients

Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.

REGN : 562.71 (+1.92%)
GSK : 39.46 (+0.74%)
MRK : 81.07 (+1.99%)
GILD : 66.86 (-0.06%)
4 Stocks with Yields Above 5% to Help Your Retirement Portfolio Grow

Because the inflationary environment and supply chain constraints could keep the overall stock market under pressure in the near term, we think it could be wise to bet on quality dividend stocks to benefit...

GSK : 39.46 (+0.74%)
FSUGY : 21.9700 (-0.27%)
KRO : 13.18 (+1.07%)
USDP : 6.76 (unch)
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion

Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.

REGN : 562.71 (+1.92%)
GSK : 39.46 (+0.74%)
MRK : 81.07 (+1.99%)
GILD : 66.86 (-0.06%)
GSK or NVO: Which Is the Better Value Stock Right Now?

GSK vs. NVO: Which Stock Is the Better Value Option?

GSK : 39.46 (+0.74%)
NVO : 104.55 (-0.10%)
Is GlaxoSmithKline (GSK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

GSK : 39.46 (+0.74%)
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab

/PRNewswire/ -- USA News Group - As vaccine passport programs continue to roll out in new markets across the globe, especially in Europe and North America, it...

BVAXF : 0.3300 (+15.47%)
NVAX : 136.86 (-14.76%)
SNY : 49.05 (+2.06%)
GSK : 39.46 (+0.74%)
INO : 7.04 (-1.26%)
Alternative Covid-19 Vaccines on the Way, as Biotech Developers Seek to Improve Upon the Jab

VANCOUVER – Biotech Today – As vaccine passport programs continue to roll out in new markets ...

BVAXF : 0.3300 (+15.47%)
NVAX : 136.86 (-14.76%)
SNY : 49.05 (+2.06%)
GSK : 39.46 (+0.74%)
INO : 7.04 (-1.26%)
BIOV.CN : 0.405 (+15.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

3rd Resistance Point 40.00
2nd Resistance Point 39.77
1st Resistance Point 39.62
Last Price 39.46
1st Support Level 39.23
2nd Support Level 39.00
3rd Support Level 38.85

See More

52-Week High 42.68
Last Price 39.46
Fibonacci 61.8% 39.08
Fibonacci 50% 37.97
Fibonacci 38.2% 36.86
52-Week Low 33.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar